跃马扬鞭开新局 砥砺奋斗创未来 国家主席习近平发表的新年贺词在南京各界引发热烈反响—— □ 南京日报/紫金山新闻记者 集体采写 "让我们拿出跃马扬鞭的勇气，激发万马奔腾的活力，保持马不停蹄的干劲，一起为梦想奋斗、为幸福打拼，把宏伟愿景变成美好现实。" "创新创造催生了新质生产力，也让生活更加多姿多彩"，东南大学首席教授、生命健康高等研究院执行院长柴人杰对此深有体会。他率领团队凭借扎实的研 究积淀，逐步成长为国内外顶尖的听觉基因治疗与干细胞治疗创新团队，不仅成功构建起覆盖内耳干细胞的全链条基因治疗技术体系，还研发优化出新型石 墨烯人工耳蜗电极，创新形成程序化人工耳蜗植入技术。如今，我国在感音神经性聋的基因治疗、干细胞治疗领域的研究与应用，已跻身国际前沿行 列。"新征程上，我们将继续完善现有基因治疗研究，不断探索前沿治疗路径，全力以赴让更多失聪人群重返有声世界。"他说。 "国家主席习近平发表的新年贺词饱含深情，温暖坚定，让我备受鼓舞。"作为一名新农人，南京市溧水区华成蔬菜专业合作社总经理冯顾城也深切感受到依 靠科技赋能农业高质量发展的重要性，他说，科技创新是农业现代化的核心驱动力，为提高生产效率，让蔬菜产业迈向规 ...

Group 1 - Xunfei Medical Technology (02506) increased by over 5.2% after shareholders committed not to reduce their holdings until December 29, 2026 [1] - Yimei International Holdings (01870) rose nearly 4% as its subsidiary's independent energy storage project was included in Guangdong's energy construction plan for 2025 [1] - Yituo Co., Ltd. (00038) slightly decreased by 0.35%, focusing on overseas business expansion and aiming to create a world-class brand [1] - Damai Entertainment (01060) surged over 5.5%, with the 2025 New Year film box office surpassing 5 billion yuan, marking a new high in eight years [1] Group 2 - Meilian Holdings (02671) fell over 18% on its second day of trading, dropping below its IPO price of 7.1 HKD [2] - Tianli International Holdings (01773) increased by over 4.4% as the Ministry of Education plans to advance AI in education [2] - Xuanwu Cloud (02392) rose by 0.87% after a major shareholder agreed to extend the lock-up period for their shares [2] - Ganfeng Lithium (01772) dropped nearly 5% due to allegations of insider trading [2] Group 3 - Boke Vision Cloud-B (02592) increased by 3.38% after a major shareholder extended the lock-up period for their shares [3] Group 4 - Yingsi Intelligent (03696) surged over 11% on its second day of trading, with a significant increase in share price from the IPO [4] - The company has developed over 20 clinical or IND application assets using its AI platform, with a total contract value of up to 2.1 billion USD [4] Group 5 - Intel (INTC.US) rose by 1.69% after Nvidia purchased 5 billion USD worth of Intel shares [5] - The global market for advanced driver assistance systems (ADAS) and autonomous driving sensors is projected to reach 61 billion USD by 2035 [6] - NIO (NIO.US) increased by 3% as it announced the global launch of its 2026 model P7+ [6] - Baidu (BIDU.US) rose by 4.39% after announcing a partnership with a logistics company to provide high-precision mapping services [6]

站在"十五五"新程待启的关键时点，如何看待2026年的经济形势？2026年经济工作怎么干？新京报贝壳财经推出《看2026：十五五·启新程》专题报道，汇 聚监管部门、知名学者和领军企业家，解读政策脉络，洞察趋势变化。 对于企业而言，针对中央经济工作会议提出的持续扩大内需等议题会有哪些举措？2026年有哪些战略发展目标？新京报贝壳财经记者就此采访了杭州医策科 技有限公司创始人兼CEO王晓梅。 通过"AI+病理CRO"双轮驱动模式，不仅高效缓解专业人才稀缺困境，更以标准化、智能化能力加速创新药械研发进程，构筑"AI赋能医药研发"的产业生态 优势。 新京报贝壳财经：2026年，公司在业绩增长、产品创新、业务线等方面有何战略发展目标？ 王晓梅：2026年，医策科技将进一步夯实医药研发病理CRO服务、医疗诊断病理AI解决方案两大核心业务，以技术创新与全球视野深化布局。 在医药研发业务上，医策科技自主研发全球首个医药研发病理CRO平台，实现从样本到报告的端到端数字化流程，提供医药研发病理中定量与半定量高影 响力分析决策支持。 在医疗诊断业务上，医策科技始终以临床需求为锚点，走差异化创新之路，产品管线上实现细胞、组织、免疫、 ...

王晓梅：当前国内病理领域供需矛盾突出：全国病理医师仅2.1万人，每百万人口仅配备14.8名病理医 生，资源分布不均且培养周期长，基层诊疗能力薄弱；医药研发端专职病理分析从业者仅300-500人， 难以匹配海量在研管线需求。对此，医策科技聚焦扩容优质供给、精准对接内需，核心战略是推动病理 AI从"效率工具"升级为"能力工具"，让AI成为具备专业决策能力的"超级助手"。 医疗端，我们加速AI病理辅助诊断场景化落地，例如在三甲医院场景对接诊疗系统，将AI病理分析嵌 入报告流程提升效率；基层通过轻量化部署，让医生低成本接入AI能力填补短板；筛查场景实现批量 样本快速分析，规避人工漏诊风险。研发端，我们基于AI能力提供细胞分型、定量分析及定性/半定量 多维评估等专业服务。 通过"AI+病理CRO"双轮驱动模式，不仅高效缓解专业人才稀缺困境，更以标准化、智能化能力加速创 新药械研发进程，构筑"AI赋能医药研发"的产业生态优势。 新京报贝壳财经：2026年，公司在业绩增长、产品创新、业务线等方面有何战略发展目标？ 站在"十五五"新程待启的关键时点，如何看待2026年的经济形势？2026年经济工作怎么干？新京报贝壳 财经推出 ...

Group 1: AI Evolution - AI has transitioned from being a remarkable "tool" to becoming a collaborative "partner" in various applications, enhancing productivity and creating new mixed-task models [3][5] - Significant advancements in AI models occurred throughout the year, including the release of Claude 3.7 Sonnet, Manus, and Gemini 3 series, showcasing improvements in multi-modal capabilities [4] - The industry is moving towards a new evaluation system that reflects AI's real-world problem-solving abilities, focusing on quantifiable ROI from AI investments [6] Group 2: Embodied Intelligence - 2025 marked the commercialization of embodied intelligence, with significant technological breakthroughs such as RoboOS and RoboBrain, lowering development barriers [9][10] - The evolution of AI is shifting towards cognitive intelligence, emphasizing the importance of real-world training and iteration for intelligent systems [9] - Embodied intelligence is enhancing human capabilities in various fields, including industrial applications and emotional companionship through AI toys and digital pets [10][11] Group 3: Healthcare Innovations - The biotech sector in China experienced explosive growth, with innovations in gene editing and domestic drugs gaining FDA approval, marking a shift from follower to leader in global healthcare [16][19] - AI is deeply integrated into life sciences, transforming drug development and precision medicine, thus reshaping the healthcare landscape [22] - High-end medical devices are advancing rapidly, with domestic innovations addressing critical needs in minimally invasive surgeries [20] Group 4: Consumer Market Dynamics - Emotional value has become a core driver of consumer behavior, with brands needing to provide deeper emotional resonance beyond basic functionality [24][26] - The retail landscape is evolving into a content-driven model, where physical stores must offer immersive experiences to attract customers [28] - Consumers are increasingly seeking seamless, personalized experiences across multiple channels, necessitating a focus on holistic customer journeys [28][29] Group 5: Entrepreneurial Mindset - Entrepreneurs are encouraged to break free from past successes that may hinder innovation, embracing unconventional thinking to navigate resource constraints [30] - Building empathy and transferable skills is essential for adapting to industry changes and enhancing team collaboration [32] - Sustainable energy management is crucial for entrepreneurs, balancing personal well-being with business growth to ensure long-term success [38]

关于公司独立董事辞任暨选举职工 董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于近日收到公司独立董事李东先生的书面辞 职报告。因公司治理结构调整，李东先生申请辞去公司第四届董事会独立董事及董事会专门委员会委 员，该辞职报告自送达公司董事会之日起生效，李东先生辞职后不再担任公司任何职务。 证券代码：603990 证券简称：麦迪科技 公告编号：2025-089 苏州麦迪斯顿医疗科技股份有限公司 ● 公司于2025年12月26日召开职工代表大会并做出决议，选举皇春萌女士担任公司第四届董事会职工董 事，任期自公司2025年第三次临时股东大会审议通过《关于取消监事会并修订〈公司章程〉的议案》之 日起至公司第四届董事会任期届满之日止。 根据《中华人民共和国公司法》（以下简称"《公司法》"）以及中国证监会《关于新〈公司法〉配套制 度规则实施相关过渡期安排》等相关规定，公司于2025年12月29日召开2025年第三次临时股东大会，审 议并通过了《公司章程》相 ...

Core Insights - Medtronic's mission is to alleviate pain, restore health, and extend life, benefiting over two patients every second globally through its medical technologies and therapies [1] - The company was recognized as the "Annual Medical Health Excellence Value Listed Company" by Caijing in 2025, highlighting its achievements and commitment to "value co-creation" in China [1] Group 1: Local Integration and Value Chain - Medtronic has established a comprehensive value chain in China, evolving from a technology exporter to a local ecosystem builder, with approximately 6,000 employees and 12 regional offices [2] - The company has developed a strategic layout that includes 1 research center, 2 innovation centers, 5 manufacturing bases, and nearly 7,000 supply chain partners, with local procurement expected to reach 5 billion RMB in FY2025 [2][3] - Medtronic's deep localization strategy is driven by a belief in China's innovation potential, having developed nearly 70 products since the establishment of its R&D center in 2012, with over 60 successfully launched [3] Group 2: Innovation and Digital Transformation - Medtronic is leveraging AI in various fields such as assisted diagnosis, digital therapy, and telemedicine, with multiple innovation hubs in China focusing on smart healthcare and new production capabilities [4] - The Shanghai factory is recognized as Medtronic's global "Best Factory," supplying products to 95 countries, while the Chengdu base is the largest insulin pump production facility outside the U.S. [4] - The establishment of a digital healthcare innovation base in Beijing in October 2025 aims to connect global innovations with the Chinese ecosystem, focusing on AI and big data solutions for disease management [3][4] Group 3: Long-term Commitment and Value Creation - Medtronic's 36-year presence in China reflects its deep integration into the local healthcare landscape, transitioning from initial technology introduction to global innovation feedback [5] - The company's approach emphasizes collaboration among engineers, clinical training, supply chain partnerships, and the intersection of innovations in smart healthcare [5] - Medtronic's commitment to "value co-creation" is seen as essential for addressing future challenges in the healthcare industry, establishing a robust foundation for sustainable growth [5]

Core Insights - A new company, Guokangbao (Shanghai) Medical Technology Co., Ltd., has been established with a registered capital of 20 million yuan [2] - The company's business scope includes wholesale of protective equipment for medical staff, sales of personal hygiene products, internet security services, data processing services, and sales of Class I medical devices [2] - The company is jointly held by Xiamen Guomao and its subsidiary, Xiamen Guomao Health Technology Co., Ltd. [2] Company Overview - Guokangbao (Shanghai) Medical Technology Co., Ltd. has a registered capital of 20 million yuan [2] - The company is involved in various sectors including medical supplies and internet services [2] Ownership Structure - The ownership of Guokangbao is linked to Xiamen Guomao and its health technology subsidiary [2]

Core Viewpoint - Recently, Guokangbao (Shanghai) Medical Technology Co., Ltd. was established with a registered capital of 20 million yuan, focusing on various healthcare-related services and products [1] Company Summary - Guokangbao (Shanghai) Medical Technology Co., Ltd. has a registered capital of 20 million yuan [1] - The company's business scope includes wholesale of protective products for medical staff, sales of personal hygiene products, internet security services, data processing services, and sales of Class I medical devices [1] - The company is jointly held by Xiamen Guomao (600755) and Xiamen Guomao Health Technology Co., Ltd. [1]

近年来，医疗健康行业正加速探索大模型、智能体等AI前沿技术的创新应用。12月29日，北京大学人 民医院（以下简称"北大人民医院"）与蚂蚁健康联合组建的"医学人工智能创新联合研究中心"正式揭牌 成立，旨在共同推动人工智能技术在医疗健康领域的前沿研究和应用落地。 同期，由北大人民医院牵头，联合中国信息通信研究院（以下简称"中国信通院"）、蚂蚁健康及多家顶 尖医院共同编制的全国首个外科领域 "AI医生" 标准正式面世，在医学AI的技术应用标准、规范上迈出 了系统化的关键一步。 北大人民医院院长、中国工程院院士王俊在揭牌仪式上表示，该研究中心将聚焦临床真实痛点，重点探 索AI在专病智能诊疗、临床决策支持及健康管理模型等方向的创新应用，全力推动将科研成果转化为 更普惠、更可及的医疗健康服务。 同时，由王俊院士等6名院士领衔，全国超500位医生已在"蚂蚁阿福"App上线了"名医AI分身"，为公众 提供7X24小时的专业健康咨询服务，让顶级专家的优秀经验更普惠地服务大众健康。 《2025年政府工作报告》明确提出加快开展"人工智能+医疗健康"工作，培育医疗健康行业新质生产 力。同年8月，国务院发布《关于深入实施"人工智能+" ...